|
|
Vaccine Comparison
|
D46/NS2/N/ΔM2-2-HindIII |
| Vaccine Information |
- Manufacturer: Charles river Laboratories
- Type: Live, attenuated vaccine
- Status: Licensed
- Host Species for Licensed Use: Human
- M2-2
gene engineering:
- Type: Deletion
- Description: (McFarland et al., 2020)The vaccine uses backbone of LId/M2-2 vaccine but has a 234 nucleotide M2-2 deletion with the same structure as in MEDI/m2-2
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
- Description: (McFarland et al., 2020)The vaccine, D46/NS2/N/ΔM2-2-HindIII, is a cDNA-derived version of RSV subgroup A, strain A2. In addition, D46/NS2/N/ΔM2-2-HindIII has the MEDI/ΔM2-2 assignments at the only 2 amino acid positions that differ between MEDI/ΔM2-2 and LID/ΔM2-2. D46/NS2/N/ΔM2-2-HindIII contains the complete 112-nucleotide 3’ noncoding region of the SH gene that is present in biological RSV A2 but was deleted in LID/ΔM2-2. D46/NS2/N/ΔM2-2-HindIII was recovered from cDNA in qualified Vero cells.
|
| References |
McFarland et al., 2020: McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski C, Thumar B, Gnanashanmugam D, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Spector SA, Aziz M, Cielo M, Beneri C, Wiznia A, Luongo C, Collins P, Buchholz UJ. Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children. The Journal of infectious diseases. 2020; 221(4); 534-543. [PubMed: 31758177].
McFarland et al., 2020: McFarland EJ, Karron RA, Muresan P, Cunningham CK, Perlowski C, Libous J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Cielo M, Wiznia A, Deville JG, Yang L, Luongo C, Collins PL, Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children. The Journal of infectious diseases. 2020; 221(12); 2050-2059. [PubMed: 32006006].
|
|
Human Respiratory Syncytial Virus M2-2 mutant vaccine |
| Vaccine Information |
- Vaccine Ontology ID: VO_0002978
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: African green monkey
- M2-2
gene engineering:
- Type: Gene mutation
- Description: This M2-2 is from Human Respiratory Syncytial Virus (Jin et al., 2003).
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
|
| References |
Jin et al., 2003: Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine. 2003; 21(25-26); 3647-3652. [PubMed: 12922094].
|
|
LID/ΔM2-2/1030s |
| Vaccine Information |
- Manufacturer: Charles River Laboratories Malvern, PA
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- M2-2
gene engineering:
- Type: Recombinant protein preparation
- Description: 241 deletion of RSV ribonucleic acid synthesis regulatory protein M2-2 (McFarland et al., 2020).
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: The vaccine, LID/ΔM2-2/1030s, is a cDNA-derived version of RSV subgroup A, strain A2 with 241 nts deleted from the M2-2 ORF and the 3 potential translation initiation codons of the M2-2 ORF silenced (McFarland et al., 2020).
|
| References |
McFarland et al., 2020: McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski C, Thumar B, Gnanashanmugam D, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Spector SA, Aziz M, Cielo M, Beneri C, Wiznia A, Luongo C, Collins P, Buchholz UJ. Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children. The Journal of infectious diseases. 2020; 221(4); 534-543. [PubMed: 31758177].
|
|
Mnull RSV |
| Vaccine Information |
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Host Species as Laboratory Animal Model: Baboons
- Antigen: Fusion (F) protein
- M protein
gene engineering:
- Type: Recombinant protein preparation
- Description: Deletion of RSV M protein. (Ivanov et al., 2021)
- Detailed Gene Information: Click Here.
- Preparation: RSV M protein was deleted (Ivanov et al., 2021).
- Immunization Route: intranasal immunization
- Description: Mnull RSV is derived from a human RSV A2 strain. The gene for the RSV M protein has been deleted. Mnull RSV is grown in HEp-2 respiratory epithelial cells transfected to express the viral M protein. The vaccine virus is fully infectious, and synthesizes all of its proteins (except M) after entering HEp-2 cells (Ivanov et al., 2021).
|
| References |
|
|
|
